Gene · 369
NIH grants1,471
NIH grants whose papers are about the gene, through NIH's grant-paper links.
141 to 160 of 1,471
Download this page as JSON| Grant | Title | ARAF papers | Newest fiscal year |
|---|---|---|---|
| P50CA168504 | Dana Farber/Harvard Cancer Center Specialized Program of Research Excellence in Breast Cancer | 1 | 2025 |
| P50CA196530 | Yale SPORE in Lung Cancer (YSILC): The Biology and Personalized Treatment of Lung Cancer | 1 | 2025 |
| P50CA217694 | SPORE in Soft Tissue Sarcoma | 1 | 2025 |
| P50CA236733 | Vanderbilt-Ingram Cancer Center SPORE in Gastrointestinal Cancer | 1 | 2025 |
| P50CA254838 | The Memorial Sloan Kettering Cancer Center SPORE in Leukemia | 1 | 2025 |
| P50HD103556 | University of Iowa Hawkeye Intellectual and Developmental Disabilities Research Center (Hawk-IDDRC) | 1 | 2025 |
| R00CA246084 | Elucidating the role of support signaling in promoting minimal residual disease in mouse models of oncogene-driven lung cancer | 1 | 2025 |
| R01AG050986 | Higher Order Chromatin and Genetic Risk for Alzheimer's Disease | 1 | 2025 |
| R01AR045192 | REGULATORS OF EPIDERMAL GENE EXPRESSION | 1 | 2025 |
| R01CA046595 | Mitogenic and Oncogenic Regulation of ERK/RSK Signaling | 1 | 2025 |
| R01CA067985 | DNA Damage Repair by MUTYH and MUTYH Variants Associated with Colorectal Cancer | 1 | 2025 |
| R01CA074305 | Chemical Approaches to Cell Signaling Enzymes | 1 | 2025 |
| R01CA120813 | Modulation of Microglia and T Cell Interactions in Malignant Glioma | 1 | 2025 |
| R01CA137008 | Non-genomic resistance mechanisms in EGFR-mutant lung cancer | 1 | 2025 |
| R01CA148706 | Targeting the colchicine binding site in tubulin for cancer therapy | 1 | 2025 |
| R01CA148761 | Therapeutic Targeting of Breast Cancer Tumor Initiating Cells | 1 | 2025 |
| R01CA163591 | Tumor cell metabolism in action | 1 | 2025 |
| R01CA164273 | Overcoming Resistance Mechanisms to Anaplastic Lymphoma Kinase Inhibitors | 1 | 2025 |
| R01CA176111 | Preventing MAPK inhibitor resistance in melanoma by targeting genomic instability and immune resistance | 1 | 2025 |
| R01CA177875 | Targeting the vasculature to enhance anti-tumor immunity | 1 | 2025 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/369/grants?page=8